Eisai Says First-Half Profit Fell 17% to 33.3 Billion Yen

Eisai Co., the maker of the Aricept treatment for Alzheimer’s disease, reported first-half profit fell 17 percent to 33.3 billion yen in a statement to the Tokyo Stock Exchange today.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.